僅用于工業應用或科學研究，不可用于人類或動物的臨床診斷或治療，非藥用. Reslizumab （Sch 55700） is humanized monoclonal antibodies that target interleukin-5 （IL-5） for the treatment of eosinophilic asthma. Reslizumab is effective in neutralizing the function of IL-5. Reslizumab has high binding affinity for human IL-5, with KD values of 109 pM and 4.3 pM in the the Biacore surface plasmon resonance and Kinetic Exclusion Assay, respectively